BioHarvest Sciences to begin human clinical study with multiple sclerosis-related optic neuritis

–News Direct–

BioHarvest Sciences CEO Ilan Sobel joined Proactive's Steve Darling to share news the company has agreed to a collaboration with the International Neurorehabilitation Institute in Maryland to perform a clinical trial to assess the capacity of the company’s red grape cell (RGC) composition to promote eye health.

RGC is produced using BioHarvest's Botanical-Synthesis technology.

Sobel told Proactive the study will be an open-label clinical study to evaluate the impact of RGC on multiple sclerosis-related optic neuritis driven by inflammation. The Multiple Sclerosis Foundation estimates more than 1 million people in the US and about 2.5 million people worldwide have been diagnosed with MS.

Contact Details

Proactive Investors Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/bioharvest-sciences-to-begin-human-clinical-study-with-multiple-sclerosis-related-optic-neuritis-205800683